For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Vyndamax and the formulated version represents a genuine breakthrough . These novel therapies protect the transthyretin protein, halting its destructive build-up and reducing the impact of the illness. Patients are now seeing positive